Los Angeles, March, 16, 2019 – AFM-Téléthon received the « Pioneer in Technology Development » award for its role in the development of innovative therapies for neuromuscular and rare diseases at the Annual World Congress of Society for Brain Mapping and Therapeutics (SBMT-Brain and Spine).
Considered as the equivalent of the Oscar for Neuroscience, the foundation’s annual fundraising gala honors individuals who have contributed to scientific discovery and achievements and helped shape public policies that have provided patients with a better quality of life.
This award acknowledges the role of AFM-Téléthon in advancing new innovative therapies for rare diseases including brain and spinal conditions. “Since the first French Téléthon in 1987, AFM-Téléthon has dedicated more than 1.3 billion dollars to therapeutic innovation to benefit patients suffering from rare diseases. It has now developed a unique capacity to design innovative biotherapies and to provide the first evidence of efficacy in patients together with an industrial platform to produce biotherapies,” said Jean-Pierre Gaspard, CEO of AMF-Téléthon, while recalling the various therapeutical breakthrough initiated since 2000.
“We are proud of this award as it shows that our expertise is acknowledged worldwide. I would like to dedicate this award to our donors and volunteers who have been supporting us in our fight to save our children since more than thirty years!” declared, Laurence Tiennot-Herment, President of AFM-Téléthon.
